Equities research analysts expect VBI Vaccines Inc (NASDAQ:VBIV) to post sales of $360,000.00 for the current quarter, according to Zacks. Two analysts have issued estimates for VBI Vaccines’ earnings, with estimates ranging from $210,000.00 to $500,000.00. VBI Vaccines reported sales of $650,000.00 in the same quarter last year, which indicates a negative year over year growth rate of 44.6%. The business is expected to announce its next earnings results on Wednesday, November 4th.
On average, analysts expect that VBI Vaccines will report full year sales of $1.42 million for the current year, with estimates ranging from $1.13 million to $1.70 million. For the next year, analysts forecast that the business will post sales of $5.26 million, with estimates ranging from $4.10 million to $6.42 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side analysts that that provide coverage for VBI Vaccines.
VBI Vaccines (NASDAQ:VBIV) last released its quarterly earnings data on Friday, July 31st. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, meeting the Zacks’ consensus estimate of ($0.04). The business had revenue of $0.18 million during the quarter, compared to analyst estimates of $0.86 million. VBI Vaccines had a negative return on equity of 46.47% and a negative net margin of 2,467.47%.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in VBIV. BlackRock Inc. boosted its stake in VBI Vaccines by 13.0% in the first quarter. BlackRock Inc. now owns 11,678,848 shares of the biopharmaceutical company’s stock valued at $11,095,000 after acquiring an additional 1,341,519 shares in the last quarter. SG Americas Securities LLC boosted its stake in VBI Vaccines by 296.1% in the first quarter. SG Americas Securities LLC now owns 55,099 shares of the biopharmaceutical company’s stock valued at $52,000 after acquiring an additional 41,189 shares in the last quarter. Rhumbline Advisers boosted its stake in VBI Vaccines by 45.6% in the first quarter. Rhumbline Advisers now owns 103,370 shares of the biopharmaceutical company’s stock valued at $98,000 after acquiring an additional 32,395 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in VBI Vaccines by 193.1% in the first quarter. Bank of New York Mellon Corp now owns 475,054 shares of the biopharmaceutical company’s stock valued at $451,000 after acquiring an additional 312,960 shares in the last quarter. Finally, Oppenheimer & Co. Inc. boosted its stake in VBI Vaccines by 64.8% in the first quarter. Oppenheimer & Co. Inc. now owns 26,200 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 10,300 shares in the last quarter. Institutional investors own 42.59% of the company’s stock.
Shares of NASDAQ VBIV traded down $0.12 during trading on Monday, reaching $2.96. 6,925,462 shares of the company traded hands, compared to its average volume of 10,427,736. The company has a current ratio of 5.86, a quick ratio of 5.77 and a debt-to-equity ratio of 0.13. VBI Vaccines has a 12-month low of $0.47 and a 12-month high of $6.93. The firm’s fifty day simple moving average is $3.55 and its 200 day simple moving average is $2.62. The stock has a market cap of $684.35 million, a P/E ratio of -11.38 and a beta of 1.79.
VBI Vaccines Company Profile
VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company offers Sci-B-Vac, a prophylactic hepatitis B vaccine for adults, children, and newborns; and eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines that closely mimic the structure of the target virus.
Read More: What is the Current Ratio?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.